Yissum - Research Development Company of the Hebrew University

Novel Compounds for the Treatment of Obesity

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Small molecule
Project ID : 6-2008-1996

Yousef Najajreh, Al Quds University

Reducing Body Weight and Glucose Levels & Improving Cognitive Function

Categories

Small molecule, obesity

Development Stage

Successful demonstration of efficacy in mice

Patent Status

US Granted patent no. 9,428,448

Novelty and IP Status

  • The patent is covering Novel Active Compounds –derivatives of fatty acids and amino acids which may regulate feeding and body weight
  • Compound X (the leading compound) and its derivatives represent novel compounds for the treatment of obesity which do not act on either CB1, TRPV1 or PPAR-α receptors (tested by MSD for receptor bindingactivity).
  • The compounds present new mechanisms of action (via POMC, NPY or FAAH (Fatty Acid Amide Hydrolase) inhibition in relation to known compounds on the market: Xenical (Lipase inhibition), Reductil (NE-5HT re-uptake inhibitor) and Rimonobant (CB1 receptor antagonist) (removed recently from the market).
  • They are made of natural products which may be given orally and act in a dose-dependent manner
  • 3 compounds improve also cognitive function as well3 compounds reduced glucose levels
  • No toxicity was found following in vivo experiments in mice ,detecting survival, neurological score and liver histopathology
  • There is a clear opportunity for an effective and well-tolerated anti-obesity drugs. Weight loss continued for 31 days after cessation of treatment and then leveled off.

Key Features

  • Patent on new compounds which are small natural, organic molecules
  • Non toxic
  • Can be delivered orally or by injection
  • Effects resemble beneficial effects of moderate caloric restriction
  • Reduce glucose blood levels
  • Improve cognition

Development Milestones

  • Continuing studies to determine optimal dosage levels and intervals
  • Toxicology studies
  • The effect on metabolic markers for diabetes and CVD

The Opportunity

  • 1.1 billion people worldwide are suffering from the health consequences of overconsumption
  • Only one drug is currently approved for long-treatment of obesity-the lipase inhibitor Xenical. Use of this product has been limited by side effects.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Jehoshua Katzhendler Z"L
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Elliot Berry
HUJI, School of Medicine - IMRIC
School of Public Health

Yosefa Avraham
HUJI, School of Medicine - IMRIC
School of Public Health

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Technologies for the food industry
  • Food quality and safety
  • Micro- and Nanotechnology related to agrofood
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Food and Beverages
  • Express Licensing
  • BioPharma

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.